*June 2022*
Highlights:
- Alternation of osimertinib and afatinib was evaluated for patients with metastatic treatment-naïve EGFR-mutated NSCLC in this phase 2 trial.
- Although the 12-month PFS probability was 70.2%, which did not meet the primary end point, the median PFS was 21.3 months suggesting the promising efficacy of this alternative therapy.
- Our results are indicative of the feasibility of alternating therapy with osimertinib and afatinib.
- The study treatment is effective even in patients with TP53 mutations or EGFR compound mutations from exploratory cfDNA analysis results
